Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Hua Zhou, Jinchun He, Bin Wu & Datian Che. (2018) Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Human Vaccines & Immunotherapeutics 14:6, pages 1444-1452.
Read now
Read now
Sabelle Jallow & Shabir A. Madhi. (2017) Pneumococcal conjugate vaccine in HIV-infected and HIV-exposed, uninfected children. Expert Review of Vaccines 16:5, pages 453-465.
Read now
Read now
Lucia Helena de Oliveira, Silas Pierson Trumbo, Cuauhtémoc Ruiz Matus, N. Jennifer Sanwogou & Cristiana M. Toscano. (2016) Pneumococcal conjugate vaccine introduction in Latin America and the Caribbean: progress and lessons learned. Expert Review of Vaccines 15:10, pages 1295-1304.
Read now
Read now
Alassane Dicko, Yahia Dicko, Amadou Barry, Youssoufa Sidibe, Almahamoudou Mahamar, Gaoussou Santara, Amagana Dolo, Aminata Diallo, Ogobara Doumbo, Fakrudeen Shafi, Nancy François, Juan Pablo Yarzabal, Ana Strezova, Dorota Borys & Lode Schuerman. (2015) Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study. Human Vaccines & Immunotherapeutics 11:9, pages 2207-2214.
Read now
Read now
Masanari Shiramoto, Shin Irie, Christine Juergens, Masako Yamaji, Satoshi Tamai, Masakazu Aizawa, Todd Belanger, William C Gruber, Daniel A Scott & Beate Schmoele-Thoma. (2014) Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged ≥50 years. Human Vaccines & Immunotherapeutics 10:7, pages 1850-1858.
Read now
Read now
Olumuyiwa O Odusanya, Yetunde A Kuyinu, Omolara A Kehinde, Fakrudeen Shafi, Nancy François, Juan Pablo Yarzabal, Kurt Dobbelaere, Jens U Rüggeberg, Dorota Borys & Lode Schuerman. (2014) Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children. Human Vaccines & Immunotherapeutics 10:3, pages 757-766.
Read now
Read now
David Pace. (2013) Glycoconjugate vaccines. Expert Opinion on Biological Therapy 13:1, pages 11-33.
Read now
Read now
Rebecca A Gladstone, Johanna M Jefferies, Saul N Faust & Stuart C Clarke. (2012) Pneumococcal 13-valent conjugate vaccine for the prevention of invasive pneumococcal disease in children and adults. Expert Review of Vaccines 11:8, pages 889-902.
Read now
Read now
Jonathan A. McCullers & Victor C. Huber. (2012) Correlates of vaccine protection from influenza and its complications. Human Vaccines & Immunotherapeutics 8:1, pages 34-44.
Read now
Read now
Articles from other publishers (32)
Sachin S. Shivatare, Vidya S. Shivatare & Chi-Huey Wong. (2022) Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments. Chemical Reviews 122:20, pages 15603-15671.
Crossref
Crossref
Anna-Lisa Sorg, Viola Obermeier, Johannes G. Liese & Rüdiger von Kries. (2021) Incidence trends of parapneumonic pleural effusions/empyema in children 2009 to 2018 from health insurance data: Only temporal reduction after the introduction of PCV13. Vaccine 39:26, pages 3516-3519.
Crossref
Crossref
Auliya A. Suwantika, Neily Zakiyah, Rizky Abdulah, Vensya Sitohang, Gertrudis Tandy, Atiek Anartati, Tetrawindu Hidayatullah, Putri Herliana & Sri R. Hadinegoro. (2021) Cost-Effectiveness and Budget Impact Analyses of Pneumococcal Vaccination in Indonesia. Journal of Environmental and Public Health 2021, pages 1-11.
Crossref
Crossref
Ben Morton, Kondwani Jambo, Tarsizio Chikaonda, Jamie Rylance, Marc Y.R. Henrion, Ndaziona Peter Banda, Edna Nsomba, Joel Gondwe, Daniela M. Ferreira & Stephen B. Gordon. (2022) The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol. Wellcome Open Research 6, pages 240.
Crossref
Crossref
Ben Morton, Kondwani Jambo, Tarsizio Chikaonda, Jamie Rylance, Marc Y.R. Henrion, Ndaziona Peter Banda, Edna Nsomba, Joel Gondwe, Daniela M. Ferreira & Stephen B. Gordon. (2021) The influence of pneumococcal conjugate vaccine-13 on nasal colonisation in a controlled human infection model of pneumococcal carriage in Malawi: a double-blinded randomised controlled trial protocol. Wellcome Open Research 6, pages 240.
Crossref
Crossref
Ravinder Mettu, Chiang-Yun Chen & Chung-Yi Wu. (2020) Synthetic carbohydrate-based vaccines: challenges and opportunities. Journal of Biomedical Science 27:1.
Crossref
Crossref
Neily Zakiyah, Widya N. Insani, Auliya A. Suwantika, Jurjen van der Schans & Maarten J. Postma. (2020) Pneumococcal Vaccination for Children in Asian Countries: A Systematic Review of Economic Evaluation Studies. Vaccines 8:3, pages 426.
Crossref
Crossref
Andrew D Wiese & Carlos G Grijalva. (2020) To Boost or Not to Boost? Lessons from the Australian Pneumococcal Conjugate Vaccination Program. Clinical Infectious Diseases 70:12, pages 2616-2618.
Crossref
Crossref
D. Goettler, A. Streng, D. Kemmling, C. Schoen, R. von Kries, M.A. Rose, M. van der Linden & J.G. Liese. (2020) Increase in Streptococcus pneumoniae serotype 3 associated parapneumonic pleural effusion/empyema after the introduction of PCV13 in Germany. Vaccine 38:3, pages 570-577.
Crossref
Crossref
Fengcai Zhu, Yuemei Hu, Jingxin Li, Qiang Ye, Mariano M. Young, John Z. Liang, William C. Gruber, Peter C. Giardina & Daniel A. Scott. (2019) Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine Administered in a 3 + 1 versus 2 + 1 Dose Schedule Among Infants in China. Pediatric Infectious Disease Journal 38:11, pages 1150-1158.
Crossref
Crossref
Lorenzo Lodi, Silvia Ricci, Francesco Nieddu, Maria Moriondo, Francesca Lippi, Clementina Canessa, Giusi Mangone, Martina Cortimiglia, Arianna Casini, Ersilia Lucenteforte, Giuseppe Indolfi, Massimo Resti & Chiara Azzari. (2019) Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Severe Invasive Disease Caused by Serotype 3 Streptococcus Pneumoniae in Italian Children. Vaccines 7:4, pages 128.
Crossref
Crossref
Beth Temple, Nguyen Trong Toan, Vo Thi Trang Dai, Kathryn Bright, Paul Vincent Licciardi, Rachel Ann Marimla, Cattram Duong Nguyen, Doan Y Uyen, Anne Balloch, Tran Ngoc Huu & Edward Kim Mulholland. (2019) Immunogenicity and reactogenicity of ten-valent versus 13-valent pneumococcal conjugate vaccines among infants in Ho Chi Minh City, Vietnam: a randomised controlled trial. The Lancet Infectious Diseases 19:5, pages 497-509.
Crossref
Crossref
Joseph J Campo, Timothy Q Le, Jozelyn V Pablo, Christopher Hung, Andy A Teng, Hervé Tettelin, Andrea Tate, William P Hanage, Mark R Alderson, Xiaowu Liang, Richard Malley, Marc Lipsitch & Nicholas J Croucher. (2018) Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination. eLife 7.
Crossref
Crossref
Lijoy Varghese, Louise Talbot, Andrea Govender, Xu-Hao Zhang & Bruce A. Mungall. (2018) A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand. Applied Health Economics and Health Policy 16:3, pages 331-345.
Crossref
Crossref
Aaradhana Singh & A. K. Dutta. (2017) Pneumococcal Vaccines – How Many Serotypes are Enough?. The Indian Journal of Pediatrics 85:1, pages 47-52.
Crossref
Crossref
Ingrid Urbancikova, Roman Prymula, David Goldblatt, Lucy Roalfe, Karolina Prymulova & Pavel Kosina. (2017) Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine 35:38, pages 5186-5193.
Crossref
Crossref
Sabelle Jallow, Shabir A. Madhi, Richard Madimabe, Nosisa Sipambo, Avy Violari, Udai Kala, Karen Petersen, Sanushka Naidoo, Charl Verwey, David P. Moore & Marta C. Nunes. (2017) Immunogenicity of 13-valent pneumococcal conjugate vaccine among children with underlying medical conditions. Vaccine 35:34, pages 4321-4329.
Crossref
Crossref
Salah Zangenah, Linda Bj?rkhem-Bergman, Anna-Carin Norlin, Susanne Hansen, Lars Lindqvist, Birgitta Henriques-Normark & Peter Bergman. (2017) The Pneumocell-study: Vaccination of IgG1- and IgG2-deficient patients with Prevnar13. Vaccine 35:20, pages 2654-2660.
Crossref
Crossref
Marcela Guevara, Aurelio Barricarte, Luis Torroba, Mercedes Herranz, Alberto Gil-Setas, Francisco Gil, Enrique Bernaola, Carmen Ezpeleta & Jesús Castilla. (2016) Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case–control study. Eurosurveillance 21:14.
Crossref
Crossref
Arto A Palmu & Helena K?yhty. (2015) Applied public health research on the frontline. The Lancet Infectious Diseases 15:4, pages 365-366.
Crossref
Crossref
Ajoke Sobanjo-ter Meulen, Timo Vesikari, Edgardo A. Malacaman, Steven A. Shapiro, Michael J. Dallas, Patricia A. Hoover, Richard McFetridge, Jon E. Stek, Rocio D. Marchese, Jonathan Hartzel, Wendy J. Watson & Luwy K. Musey. (2015) Safety, Tolerability and Immunogenicity of 15-valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated With 7-valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal 34:2, pages 186-194.
Crossref
Crossref
Jesús Feris-Iglesiasa, Josefina Fernández, Jacqueline Sánchez, Fabiana Pimenta, Chabela Peña, Hilma Coradin, Eddy Perez-Thena, Maria Peinadoc, Angélica Floren, Teresa Del Moral, Dean Erdmanb, Maria da Gloria Carvalhob & Jennifer R. Verani. (2014) Aetiology of paediatric pneumonia with effusion in the Dominican Republic and the potential impact of pneumococcal conjugate vaccines. Pneumonia 4:1, pages 8-15.
Crossref
Crossref
Nopporn Apiwattanakul, Paul G. Thomas, Amy R. Iverson & Jonathan A. McCullers. (2014) Chronic helminth infections impair pneumococcal vaccine responses. Vaccine 32:42, pages 5405-5410.
Crossref
Crossref
Angel Vila-Corcoles & Olga Ochoa-Gondar. (2014) Pneumococcal conjugate vaccination: correlates of protection. The Lancet Infectious Diseases 14:9, pages 784-786.
Crossref
Crossref
Shifeng Wang & Roy Curtiss III. (2014) Development of Streptococcus pneumoniae Vaccines Using Live Vectors. Vaccines 2:1, pages 49-88.
Crossref
Crossref
Jason W Rosch, Amy R Iverson, Jessica Humann, Beth Mann, Geli Gao, Peter Vogel, Michael Mina, Kyle A Murrah, Antonia C Perez, W Edward Swords, Elaine I Tuomanen & Jonathan A McCullers. (2013)
A live‐attenuated pneumococcal vaccine elicits
CD
4
+
T
‐cell dependent class switching and provides serotype independent protection against acute otitis media
. EMBO Molecular Medicine 6:1, pages 141-154.
Crossref
Crossref
Anneke Steens, Marianne A. Riise Bergsaker, Ingeborg S. Aaberge, Karin Rønning & Didrik F. Vestrheim. (2013) Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway. Vaccine 31:52, pages 6232-6238.
Crossref
Crossref
Ron Dagan, Scott Patterson, Christine Juergens, David Greenberg, Noga Givon-Lavi, Nurith Porat, Alejandra Gurtman, William C. Gruber & Daniel A. Scott. (2013) Comparative Immunogenicity and Efficacy of 13-Valent and 7-Valent Pneumococcal Conjugate Vaccines in Reducing Nasopharyngeal Colonization: A Randomized Double-Blind Trial. Clinical Infectious Diseases 57:7, pages 952-962.
Crossref
Crossref
Kenneth K.C. Lee, David Bin Chia Wu, Oleksandr Topachevskyi, Emmanuelle Delgleize & Rodrigo DeAntonio. (2013) The Health Economic Impact of Universal Infant Vaccination with the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine as Compared with 13-Valent Pneumococcal Conjugate Vaccine in Hong Kong. Value in Health Regional Issues 2:1, pages 64-74.
Crossref
Crossref
Carmen Muñoz-Almagro, Adoracion Navarro-Torne & Roman Pallares. (2013) Epidemiologic and Clinical Implications of Second-Generation Pneumococcal Conjugate Vaccines. Current Infectious Disease Reports 15:2, pages 184-190.
Crossref
Crossref
Sam Mehr & Nicholas Wood. (2012) Streptococcus pneumoniae – a review of carriage, infection, serotype replacement and vaccination. Paediatric Respiratory Reviews 13:4, pages 258-264.
Crossref
Crossref
Carole Harfouche, Sara Filippini, Claudia Gianfaldoni, Paolo Ruggiero, Monica Moschioni, Silvia Maccari, Laura Pancotto, Letizia Arcidiacono, Bruno Galletti, Stefano Censini, Elena Mori, Marzia Giuliani, Claudia Facciotti, Elena Cartocci, Silvana Savino, Francesco Doro, Michele Pallaoro, Salvatore Nocadello, Giuseppe Mancuso, Mitch Haston, David Goldblatt, Michèle A. Barocchi, Mariagrazia Pizza, Rino Rappuoli & Vega Masignani. (2012)
RrgB321, a Fusion Protein of the Three Variants of the Pneumococcal Pilus Backbone RrgB, Is Protective
In Vivo
and Elicits Opsonic Antibodies
. Infection and Immunity 80:1, pages 451-460.
Crossref
Crossref